Product Information

LAMIVUDINE 300 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $1.3014 per EA under NDC 65862002630. Its NADAC has been published 324 times since Apr 18, 2018.

LAMIVUDINE 300 MG TABLET

Lamivudine
$1.3014per EA

Strength

300 mg/1

NDC

65862002630

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

8/20/2025

Active Ingredients

LAMIVUDINE

Approval Type

Generic (ANDA)

FDA Application

ANDA077464

On Market Since

11/21/2016

Price Statistics

The NADAC for LAMIVUDINE 300 MG TABLET has been published 324 times since Apr 18, 2018, and over the history we have for it it has declined 58.0%. The table below summarizes its recorded NADAC range and movement.

Current price$1.3014 per EA
All-time high$3.0970 (Jun 13, 2018)
All-time low$1.1052 (Jan 22, 2020)
52-week high$1.5066
52-week low$1.3014
Median price$1.6132
Average price$1.6516
Largest weekly change+54.2% (Feb 17, 2021)
Weeks tracked324
Tracking sinceApr 18, 2018

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

-13.6%

3Y

+0.7%

5Y

-25.9%

All

-58.0%

Generic Alternatives

The matcher finds 3 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 3 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of LAMIVUDINE 300 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE 300 MG TABLET, manufactured by Aurobindo Pharma Limited, is $1.3014 per EA (NDC 65862002630), effective Aug 20, 2025.

How has the price of LAMIVUDINE 300 MG TABLET changed over time?

Over the history we have for it, the NADAC for LAMIVUDINE 300 MG TABLET has declined 58.0%. It has been tracked across 324 weekly CMS publications since Apr 18, 2018.

What are the highest and lowest recorded NADAC prices for LAMIVUDINE 300 MG TABLET?

Since Apr 18, 2018, the NADAC for LAMIVUDINE 300 MG TABLET has ranged from a low of $1.1052 (Jan 22, 2020) to a high of $3.0970 (Jun 13, 2018), with a median of $1.6132 per EA.

Are there cheaper alternatives to LAMIVUDINE 300 MG TABLET?

3 NADAC-published products share the same active ingredient, strength, and dosage form as LAMIVUDINE 300 MG TABLET, but none are currently priced below it.

Who manufactures LAMIVUDINE 300 MG TABLET?

LAMIVUDINE 300 MG TABLET (NDC 65862002630) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.